Skip to content
Acting Auditions – Lifestyle
Author:
Revive Therapeutics Ltd.
Revive Therapeutics Reports Grant of Options
August 14, 2026
Revive Therapeutics Announces Strategic Expansion of Bucillamine Program Across Infectious Diseases, Defence and Biothreat Medical Countermeasures
May 20, 2026
Realty Income Announces Operating Results for the Three Months Ended March 31, 2026
May 8, 2026
Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases
March 11, 2026